Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Updated June 2026 · ClinicalTrials.gov

Roswell Park Cancer Institute

Reviewed by TrialFinderData Editorial Team · Updated

6 clinical trials · 6 recruiting · OTHER

Roswell Park Cancer Institute has 6 clinical trials registered on ClinicalTrials.gov, with 6 actively recruiting participants. The trials listed below cover 20 conditions across the phases listed in the sidebar. Always discuss any specific trial with your physician before contacting a study site.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About Roswell Park Cancer Institute\'s Trial Portfolio

Roswell Park Cancer Institute is a non-industry sponsor (academic medical center, hospital, foundation, or research network). Non-industry sponsors often investigate novel approaches, rare conditions, and behavioral or surgical interventions that commercial sponsors may not prioritize.

6 of Roswell Park Cancer Institute's 6 registered trials are currently recruiting — roughly 100% of the portfolio. A high recruiting share usually points to an active research pipeline with multiple programs at the enrollment stage.

Roswell Park Cancer Institute's research footprint spans Recurrent Fallopian Tube Carcinoma (2 trials), Recurrent Ovarian Carcinoma (2), and Recurrent Primary Peritoneal Carcinoma (2) as the top three conditions. The full condition list, sorted by trial count, is in the sidebar.

Phase 2 is the largest single phase in Roswell Park Cancer Institute's portfolio at 33% of registered trials. The full phase breakdown appears in the sidebar.

Trials by Roswell Park Cancer Institute

RECRUITINGPhase 3NCT06563388

Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial

This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on...

Sponsor: Roswell Park Cancer InstituteEnrolling: 8001 location
OligometastasisLung CancerColo-rectal Cancer+1
RECRUITINGPhase 2NCT05231122

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With...

This phase II trial tests whether pembrolizumab combined with bevacizumab with or without agonist anti-CD40 CDX-1140 works to shrink tumors in patients with ovarian cancer that...

Sponsor: Roswell Park Cancer InstituteEnrolling: 802 locations
Ovarian Clear Cell AdenocarcinomaPlatinum-Sensitive Ovarian CarcinomaRecurrent Endometrial Serous Adenocarcinoma+12
RECRUITINGNCT06855706

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage...

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on physical activity...

Sponsor: Roswell Park Cancer InstituteEnrolling: 1201 location
Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+10
RECRUITINGNCT06414317

An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally...

This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has...

Sponsor: Roswell Park Cancer InstituteEnrolling: 1601 location
Locally Advanced Bladder CarcinomaMetastatic Bladder CarcinomaStage III Bladder Cancer AJCC v8+2
RECRUITINGPhase 2NCT06627751

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients...

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of...

Sponsor: Roswell Park Cancer InstituteEnrolling: 281 location
Extramedullary Disease in Multiple MyelomaRecurrent Multiple MyelomaRefractory Multiple Myeloma
RECRUITINGPhase 1NCT06305598

Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration...

This phase I trial tests the change in androgen receptor sensitivity, side effects and effectiveness of bipolar androgen therapy, using testosterone, in patients with castration...

Sponsor: Roswell Park Cancer InstituteEnrolling: 141 location
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8

How to Approach a Trial Listing

Each trial card above links to a dedicated page with the official ClinicalTrials.gov data plus a plain-English translation of the eligibility criteria. We translate technical terminology (ECOG performance status, hepatic function values, exclusionary lab thresholds) into language that a patient or caregiver can understand, but the original clinical text and the live ClinicalTrials.gov record always govern any actual eligibility decision.

Before contacting a trial site, write down questions for your treating physician using the framework on our 25 Questions guide. Discuss whether the trial fits your treatment plan, what the time commitment looks like, and whether your insurance will cover the standard-of-care portions. Trials are not a substitute for a treatment plan — they are an addition that needs medical guidance to evaluate.

Authoritative Resources

Verify any trial registration directly on ClinicalTrials.gov. For background on the FDA approval pathway that Phase 3 trials feed into, see the FDA drug approval process. For cancer-specific trial guidance, the National Cancer Institute publishes patient-oriented overviews. For global trial registrations beyond the U.S., the WHO ICTRP aggregates registries from around the world.

Frequently Asked Questions

How many clinical trials does Roswell Park Cancer Institute have on ClinicalTrials.gov?

Roswell Park Cancer Institute has 6 clinical trials registered on the federal ClinicalTrials.gov registry, of which 6 are actively recruiting participants right now. These counts come directly from the ClinicalTrials.gov API and are updated as the registry changes.

What conditions does Roswell Park Cancer Institute study?

Roswell Park Cancer Institute's registered trials cover 20 conditions on ClinicalTrials.gov, led by Recurrent Fallopian Tube Carcinoma (2 trials), Recurrent Ovarian Carcinoma (2 trials), Recurrent Primary Peritoneal Carcinoma (2 trials), Oligometastasis (1 trial), Lung Cancer (1 trial). The complete condition list appears in the sidebar of this page; each condition links to a page listing every recruiting trial in that area, regardless of sponsor.

How do I join a Roswell Park Cancer Institute clinical trial?

Joining a clinical trial is a medical decision that should always involve your treating physician. Each trial page on this site includes the eligibility criteria translated into plain English alongside the official clinical text, plus the contact information that the sponsor has registered with ClinicalTrials.gov. Bring the trial information to your doctor before reaching out — they can review the full inclusion and exclusion criteria against your medical history and help you decide whether to pursue screening.

What does the trial phase mean?

Phase 1 trials test safety and dosing in small groups (often 20–80 healthy volunteers or patients). Phase 2 trials evaluate efficacy and side effects in larger groups (100–300 patients with the target condition). Phase 3 trials confirm efficacy and monitor safety in the largest groups (300–3,000+ patients) and form the basis of an FDA approval submission. Phase 4 studies happen after a treatment is approved, monitoring long-term safety and effectiveness in real-world use. Some trials register without a phase — common for device, behavioral, or observational studies.

Where does this trial data come from?

All trial data is pulled directly from the ClinicalTrials.gov API v2, the official federal trial registry maintained by the National Library of Medicine at NIH. Under FDAAA 801, most U.S. drug and device trials are required to register, making ClinicalTrials.gov the most comprehensive source. Sponsors are responsible for keeping their listings current; trial status can shift between data refreshes.

How This Sponsor Page Is Built

Every count on this page is derived directly from ClinicalTrials.gov API v2 records. Trial counts include all trials currently registered to this sponsor; the recruiting count reflects trials with status "Recruiting" or equivalent. Plain-English eligibility translations on each linked trial page preserve the original clinical text alongside an accessible version. Read the full methodology for the data pipeline and limitations.

Source: ClinicalTrials.gov API v2, maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-06-26 · 6 trials tracked for Roswell Park Cancer Institute.